The protective effects of beta-lactam antibiotics in motor neuron disorders

  title={The protective effects of beta-lactam antibiotics in motor neuron disorders},
  author={Eva Hedlund},
  journal={Experimental Neurology},
  • E. Hedlund
  • Published 1 September 2011
  • Biology, Psychology
  • Experimental Neurology

The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury

In vivo evidence is provided that CTX could exert neuroprotective effect against TBI by improving cognitive function and alleviating brain edema via reducing excitotoxicity and inflammation after TBI.

Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson’s disease dementia

Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence

The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats.

Findings of detrimental effects on motor functional outcome suggest that ceftriaxone may be more useful for neuroprotection during the acute phase of ischemia than for functional recovery in the post-acute period after ischemic damage.

Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents

  • M. Labro
  • Biology
    Expert review of anti-infective therapy
  • 2012
The first part of this review focuses on the potential immunomodulating properties of anti-infective agents, beginning with antibacterial and antiviral agents.

A Physical-Chemical Study of the Interference of Ceftriaxone Antibiotic with Copper Chloride Salt

It was observed that (CFT) has a higher zone of inhibition and antibacterial activity than that of bulk and nano-Cu-CFT complexes in Klebsiella pneumonia and Pseudomonas aeruginosa (gram-negative bacteria).

Towards a general synthesis of 3-metal-substituted β-lactams.

The cis/trans selectivity of the reactions ranges from low in complexes containing the alkyne moiety joined directly to the cyclopentadienyl ring to complete when the metal moiety is separated from the reactiveAlkyne by an alkynyl-aryl fragment.



β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

Using a blinded screen of 1,040 FDA-approved drugs and nutritionals, it is discovered that many β-lactam antibiotics are potent stimulators of GLT1 expression, and this action appears to be mediated through increased transcription of theGLT1 gene.

Clinical trials for neuroprotection in ALS.

A number of more or less established agents have recently been investigated also in ALS for their potential role in neuroprotection and relying on antiglutamatergic, antioxidant or antiapoptotic strategies, and new therapies have also been identified.

Mechanism of Ceftriaxone Induction of Excitatory Amino Acid Transporter-2 Expression and Glutamate Uptake in Primary Human Astrocytes*

The data indicate that ceftriaxone is a potent modulator of glutamate transport in PHFA through NF-κB-mediated EAAT2 promoter activation, and suggest a mechanism for ceftRIaxone modulation of glutamate Transport and for its potential effects on ameliorating specific neurodegenerative diseases through modulation of extracellular glutamate.

Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)

Transgenic overexpression of Cu+2/Zn+2 superoxide dismutase 1 (SOD1) harboring an amyotrophic lateral sclerosis (ALS)-linked familial genetic mutation (SOD1G93A) in a Sprague–Dawley rat results in

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.

In fibroblast cultures derived from SMA patients treated with therapeutic doses of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold, and VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats and increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing.

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

Developing C‐terminal, antioligopeptide antibodies that were specific for each glutamate transporter subtype found that GLT‐1 immunoreactive protein was severely decreased in ALS, both in motor cortex (71% decrease compared with control) and in spinal cord.

Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis

A difference in EAAT1 and EAAT2 immunoreactivity in different stages of progression in ALS is demonstrated, as a feature of the pathomechanism of this disease.

Spinal muscular atrophy: mechanisms and therapeutic strategies.

The natural history of SMA has been altered over the past several decades, primarily through supportive care measures, but an effective treatment does not presently exist and the common genetic etiology and recent progress in pre-clinical models suggest that SMA is well-suited for the development of therapeutic regimens.